An interventional study of Remote Blood Pressure Monitoring + Telehealth in Hypertension and Blood Pressure Monitoring, sponsored by University of Alabama at Birmingham. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment
The overall goal of this project is to determine if measuring blood pressure at home and staying in contact with a team of pharmacists and physicians to manage participants' blood pressure is useful. The study will enroll 552 participants who are seen at the University of Alabama at Birmingham 1917 Dewberry Clinic and Vanderbilt Comprehensive Care Center. Half of the participants (276 patients) will be asked to measure blood pressure at home, and half of the participants (276 patients) will continue to receive usual care. Participants who measure blood pressure at home will also meet with a pharmacist weekly over the phone to discuss blood pressure readings and have blood pressure medications prescribed if needed. This program will last 6 months.
For all participants:1. Participants will receive information on the importance of measuring blood pressure and ways to improve blood pressure. 2. Participants will complete questionnaires describing current socioeconomic position, medical history and healthcare needs. 3. Participants will come in for three research clinic visits to get blood pressure measured 3 months after enrollment in this study, and 6 months after enrollment in this study.
For participants asked to measure blood pressure at home: 1. Measure blood pressure twice a day at home, following the instructions provided. The study will provide participants with the device and send text message reminders twice a week. Participants will return the device at study visit 3 months from now. 2. Following the instructions provided, participants will talk to a pharmacist over the phone weekly to discuss blood pressure and medications. All medication changes will be discussed with a collaborating physician. 3. Participants will complete questionnaires and interviews on satisfaction with the program.
Exclusion Criteria:
Participants will undergo remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
Behavioral: Remote Blood Pressure Monitoring + Telehealth
Participants receive usual care from providers to manage blood pressure
Participants will undergo remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
Also known as: Intervention group
Total Number of Enrolled Participants with Blood Pressure Control
The number of enrolled participants with blood pressure control
Time frame: Time Frame: 12 weeks (3 months) from randomization
Number of Participants in the Intervention with Patient-Reported Outcomes
The number of participants with completed qualitative interviews and surveys regarding intervention adherence and satisfaction. The survey will assess intervention adherence and satisfaction using the following scales: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and the Feasibility of Intervention Measure (FIM). The AIM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better acceptability while the lower total score indicates worse acceptability. The IAM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better appropriateness while the lower total score indicates worse appropriateness. The FIM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better feasibility while the lower total score indicates worse feasibility.
Time frame: Time Frame: 24 weeks (6 months) from randomization
No study locations are listed for this record.
Plan to share: No — While the investigators do not anticipate generating research tools, the investigators are committed to adhering to the National Institutes of Health (NIH) Research Tools Policy to ensure that any resources developed under this award are readily available to qualified researchers. If an NIH-defined research tool is developed, the investigators will collaborate with University of Alabama at Birmingham Commercialization and Licensing Office and all participating institutions to define ownership, protect intellectual property, and establish a dissemination strategy that ensures appropriate access and compliance with NIH guidelines.
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham